As seen on:
As seen on:
Latest Articles
We look at tighter rules for suspended companies, Singapore’s growing IPO pipeline, Beijing’s clampdown on illicit cross-border stock trading and a landmark office complex attracting billion-dollar interest.
A S$10,000 investment in the SPDR STI ETF grew to around S$26,220 over 10 years, including dividends. Here’s what Singapore investors can learn.
Three SGX-listed small-caps are paying dividends – but each faces a very different test ahead. Here’s what to watch in their upcoming earnings.
As June approaches, these three companies stand out for generating reliable cash flow and maintaining stable dividend payouts despite ongoing market uncertainty.
Singapore’s largest REITs are spending billions to reshape their portfolios. But will these deals actually grow your DPU?
Building your first S$50,000 may feel overwhelming after graduation, but a disciplined investing plan can accelerate wealth creation surprisingly quickly.
Popular
We compare two popular Mapletree REITs to determine which makes the better investment choice.
Discover which three Singapore blue-chip dividend stocks offer income, resilience, and the potential to help investors stay ahead of rising living costs.
Three blue chips are reshaping their portfolios through billion-dollar deals, asset sales, and strategic pivots.
Some stocks come and go in a portfolio. But a select group of blue-chip companies have the durability, earnings power, and discipline to justify holding them for decades.
Stocks
Singapore bank shares are trading near record highs, prompting many investors to wonder whether they have missed the opportunity. Here’s what long-term investors should focus on before making their next move.
Singapore’s big three banks beat the STI in the first half of 2026, here’s how.
Genting Singapore’s dividend yield has climbed close to 7%, making it one of the more attractive income plays on the SGX. But can the casino operator continue paying such generous dividends?
Three SGX companies raised their dividends this year — but only some of that income is built to last. Here’s how to tell which payout repeats and which was a one-off.
Getting Started
Will technology stocks remain relevant in the brave new world?
The world faces a different kind of problem aside from the pandemic, but one that can be tackled with pharmaceuticals.
With a potential rocky and unsteady recovery post-COVID-19, here’s how you can locate stocks that will do well.
As enticing and appealing as cash might be, the problem is that there is a cost associated with keeping it.